企業プロフィール
United Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- UTHR
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
512.88 USD (-0.05%)
終値
最終更新: 2026年8月24日
22.9B USD
時価総額
株価変動の要因
As of Aug 24, 2026, UTHR was little changed and closed at $512.88. No new same-company headline was identified in the current news window.
企業概要
事業概要
United Therapeutics is a biotechnology company focused on therapies for pulmonary arterial hypertension and other severe chronic conditions. Its business has long been anchored by a small number of highly differentiated commercial products and a pipeline aimed at expanding that footprint.
所在地とセクター分類
Headquartered in the United States and listed on NASDAQ, United Therapeutics has a U.S.-centered commercial and development profile. It sits in specialty biotech with a strong rare-disease and pulmonary-hypertension identity.
ビジネスモデルの特徴
The company combines commercial product revenue with pipeline expansion, manufacturing discipline, and long-duration disease management. Investors watch product demand, label breadth, and whether the company can continue extending its franchise into new pulmonary indications.
バイオ業界での位置付け
United Therapeutics occupies a premium niche within biotech because it has already proved it can commercialize highly specialized therapies. It remains catalyst-sensitive, but the business is more durable than a pure early-stage biotech name.
今後のカタリスト
- United Therapeutics’ next catalysts are Tyvaso DPI growth, pulmonary-hypertension expansion, and any additional inhaled-treprostinil data. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
最近のニュース
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。